… therapy with apalutamide in patients with metastatic, castration-sensitive prostate cancer led
… trial involving patients with metastatic, castration-sensitive prostate cancer, including those …

… that outcomes for patients with metastatic castration-sensitive prostate cancer (mCSPC)
are … These treatments are now considered standard of care and included in prostate cancer …

… (defined as not receiving ADT at the time of metastatic … response system, to receive oral
apalutamide (four 60 mg tablets, … for metastatic castration-sensitive prostate cancer were allowed. …

… Prostate cancer affects one in nine men and once metastatic is incurable. The treatment for
metastatic castration-sensitive prostate cancer … , enzalutamide, apalutamide) or docetaxel in …

… Based on the primary results of the TITAN study, apalutamide has been approved in … of
men with metastatic castration-sensitive prostate cancer (mCSPC). The effect of apalutamide on …

… metastatic castration-sensitive prostate cancer (mCSPC). In a multinational, phase III study
(TITAN) in this patient population, the addition of apalutamide … addition of apalutamide to ADT …

… 883P Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive
prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation …

… apalutamide + … Apalutamide + androgen deprivation therapy can be considered as one of
the therapeutic options for a broad spectrum of metastatic castration-sensitive prostate cancer …

… In prostate cancer, AR is expressed in the cancerous cells throughout cancer progression,
both in the castration-sensitive and -resistant states [Citation36]. Activation of the AR results in …

… apalutamide have transformed the management of patients with advanced prostate cancer
by … Results are currently awaited from ongoing studies of apalutamide in prostate cancer with …